Search
Close this search box.

BRONCHIECTASIS

Z7224L01

STUDY OUTLINE

The study aims to evaluate the effect of inhaled colistimethate sodium (study drug) compared with no study drug on the frequency of exacerbations (chest flare ups) and the number of exacerbation-free days over the 12 month treatment period.

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged 18 or over with a diagnosis of non-cystic fibrosis bronchiectasis by CT scan.
  • At least two flare ups of your bronchiectasis requiring oral antibiotic treatment in the last 12 months (or one requiring intravenous antibiotic treatment in the last 12 months).
  • Sputum tested positive for P. Aeuruginosa in the last 12 months.

WHAT'S INVOLVED

  • You will be required to attend up to 7 visits to the Institute for Respiratory Health at Level 2, 6 Verdun Street, Nedlands WA 6009 and complete 2 phone calls for up to approximately 14 months.

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top